Summary of Significant Accounting Policies and Select Balance Sheet Information (Tables)

12 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Amortized Cost, Unrealized Holding Gains (Losses) and Fair Value of Available for Sale Securities

The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities as of September 30, 2017 and 2016 were as follows (in thousands):

	September 30, 2017
(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Commercial paper and corporate bonds	$	31,817	$	—	$	(15	)	$	31,802
Total	$	31,817	$	—	$	(15	)	$	31,802

	September 30, 2016
(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Commercial paper and corporate bonds	$	22,019	$	—	$	(65	)	$	21,954
Total	$	22,019	$	—	$	(65	)	$	21,954

Components of Inventories

Inventories consisted of the following components as of September 30 (in thousands):

	2017		2016
Raw materials	$	1,603	$	1,766
Work in-process		659		492
Finished products		1,254		1,321
Total	$	3,516	$	3,579

Schedule of Property, Plant and Equipment

Property and equipment consisted of the following components as of September 30 (in thousands):

	Useful Life	2017			2016
	(In years)
Land	N/A	$	4,420		$	4,359
Laboratory fixtures and equipment	3 to 10		19,491			15,243
Buildings and improvements	3 to 20		21,924			19,589
Office furniture and equipment	3 to 10		4,541			3,948
Construction-in-progress			2,493			3,441
Less accumulated depreciation			(29,927	)		(26,979	)
Property and equipment, net		$	22,942		$	19,601

Summary of Other Assets

Other assets consist principally of the following as of September 30 (in thousands):

	2017		2016
ViaCyte, Inc.	$	479	$	479
Other noncurrent assets		418		149
Other assets, net	$	897	$	628

Schedule of Intangible Assets

Intangible assets consisted of the following as of September 30 (in thousands):

	2017
	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	18,293	$	(7,834	)	$	10,459
Developed technology		11.7		9,297		(1,478	)		7,819
Non-compete		5.0		230		(103	)		127
Patents and other		16.5		2,321		(1,423	)		898
Subtotal				30,141		(10,838	)		19,303
Unamortized intangible assets:
In-process research and development				679		—			679
Trademarks and trade names				580		—			580
Total			$	31,400	$	(10,838	)	$	20,562

	2016
	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	17,692	$	(6,123	)	$	11,569
Core technology		8.0		530		(530	)		—
Developed technology		11.8		8,724		(618	)		8,106
Non-compete		5.0		230		(58	)		172
Patents and other		16.5		2,321		(1,275	)		1,046
Subtotal				29,497		(8,604	)		20,893
Unamortized intangible assets:
In-process research and development				987		—			987
Trademarks and trade names				645		—			645
Total			$	31,129	$	(8,604	)	$	22,525

Estimated Amortization Expense

Based on the intangible assets in service, excluding any possible future amortization associated with acquired IPR&D, which has not met technological feasibility as of September 30, 2017, estimated amortization expense for each of the next five fiscal years is as follows (in thousands):

2018	$	2,661
2019		2,661
2020		2,486
2021		2,347
2022		2,307

Schedule Of Carrying Amount Of Goodwill By Segment

The change in the carrying amount of goodwill by segment for the years ended September 30, 2017 and 2016 was as follows (in thousands):

(Dollars in thousands)	In Vitro Diagnostics		Medical Device		Total
Balance as of September 30, 2015	$	8,010	$	—	$	8,010
Additions (See Note 3)		—		17,892		17,892
Foreign currency translation adjustment		—		653		653
Balance as of September 30, 2016		8,010		18,545		26,555
Foreign currency translation adjustment		—		727		727
Balance as of September 30, 2017	$	8,010	$	19,272	$	27,282

Schedule of Other Accrued Liabilities

Other accrued liabilities consisted of the following as of September 30 (in thousands):

	2017		2016
Accrued professional fees	$	501	$	262
Accrued clinical study expense		411		283
Accrued inventory purchases		596		315
Due to customers		41		881
Deferred revenue		62		180
Other		224		249
Total	$	1,835	$	2,170

Denominator for Computation of Basic and Diluted Income Per Share

The following table sets forth the denominator for the computation of basic and diluted income per share for each of the fiscal years ended September 30 (in thousands):

	2017		2016		2015
Net income from continuing operations available to common shareholders	$	3,926	$	9,985	$	11,947
Basic weighted average shares outstanding		13,153		12,998		13,029
Dilutive effect of outstanding stock options, non-vested    restricted stock, restricted stock units and performance    shares		236		221		260
Diluted weighted average shares outstanding		13,389		13,219		13,289